



Sinclair Pharma plc

(the "Company")

Annual Information Update

26 November 2009, Godalming, UK: Sinclair Pharma Plc, the international specialty pharma company, is pleased to provide an annual information update in accordance with the requirements of Prospectus Rule 5.2.1R, of information that has been published or made available to the public for the period from 16 November 2008 to date. The information referred to in this update was current at the time the information was published but some information may now be out of date.

1. Announcements made via a Regulatory Information Service

The Company made the following regulatory announcements via the Regulatory News Service on or around the dates indicated:

Date	Announcement
24/11/2009	Publication of Prospectus
23/11/2009	Jerry Randall to step down as CFO
19/11/2009	Interim Management Statement
12/11/2009	Sinclair, Orapharma terminate US Decapinol agreement
11/11/2009	Result of General Meeting
02/11/2009	Annual Report & Accounts
29/10/2009	New Debt Facility
12/10/2009	Acquisition of Flammazine and Flammacerium from Solvay
12/10/2009	Preliminary results for the year ended 30 June 2009
05/10/2009	Re-Convertible Unsecured Loan Note
23/09/2009	Re-Convertible Unsecured Loan Note
23/09/2009	INVESCO Limited Rule 8.3 – Sinclair Pharma plc
22/09/2009	Statement re Share Price Movement
14/09/2009	Second Price Monitoring Extension
14/09/2009	Price Monitoring Extension
07/09/2009	Placement of Convertible Unsecured Loan Notes
28/08/2009	Total Voting Rights



17/08/2009	Blocklisting Interim Review
04/08/2009	Sebclair launched in US
22/07/2009	Trading update for the year ending 30 June 2009
15/06/2009	Holding(s) in Company
18/05/2009	Interim Management Statement
22/04/2009	Change of Adviser
18/03/2009	Second Price Monitoring Extension
18/03/2009	Price Monitoring Extension
03/03/2009	Change of Adviser
26/02/2009	Interim Results
20/02/2009	Sinclair Pharma signs agreements with BMG Pharma
13/02/2009	Notice of Results
09/02/2009	Blocklisting Interim Review
05/02/2009	Holding(s) in Company
04/02/2009	Sinclair strengthens European sales and marketing
23/01/2009	Holding(s) in Company
07/01/2009	Agreement signed with Graceway for Atopicclair in US
31/12/2008	Total Voting Rights
22/12/2008	Sinclair Pharma announces sales collaboration
12/12/2008	Director/PDMR Shareholding
11/12/2008	Grant of Share Awards under Long-term Incentive Plan
08/12/2008	Result of AGM
08/12/2008	Placing
28/11/2008	Total Voting Rights
20/11/2008	Annual Information Update
18/11/2008	Additional Listing

2. Documents filed at Companies House



Type	Date	Description
MG02	25/11/2009	Declaration of satisfaction in full or in part of a mortgage or charge
MG02	25/11/2009	Declaration of satisfaction in full or in part of a mortgage or charge
88(2)	14/09/2009	Issue of 9,189 ordinary 1p shares at 1p each on 30 June 2009
88(2)	06/03/2009	Issue of 7,000,000 ordinary 1p shares at 16p each on 8 December 2008
88(2)	06/03/2009	Issue of 1,956,521 ordinary 1p shares at 23p each on 12 November 2008
88(2)	02/03/2009	Capitals not rolled up
88(2)	23/01/2009	Issue of 400,000 ordinary 1p shares at 23p each on 18 November 2008
363a	19/12/2008	Annual Return
AA	17/12/2008	Group of companies accounts made up to 30 June 2008
288b	10/12/2008	Resignation of Ralph Steven Harris as a director
RES10	10/12/2008	Authorised allotment of shares and debentures
RES01	10/12/2008	Alteration to memorandum and articles
RES09	10/12/2008	Authority – purchase shares other than from capital
RES11	10/12/2008	Disapplication of pre-emption rights

Copies of documents filed at Companies House can be obtained from the Companies House website at www.companieshouse.gov.uk or Companies House, Crown Way, Cardiff F14 3UZ.

3. Additional Documents

The Company submitted copies of the following documents to the UK Listing Authority, which have also been provided to shareholders:

Date	Document
24/11/2009	Prospectus in connection with the acquisition of the Solvay Products, firm placing and placing and open offer of 56,731,322 new ordinary shares at 32 pence per new ordinary share and Notice of General Meeting
02/11/2009	Annual report and accounts for the year ended 30 June 2008 and



	Notice of Annual General Meeting
26/02/2009	Interim report for the six months to 31 December 2008

All of the documents listed above can be obtained from the Company's website www.sinclairpharmair.com and are available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25, The North Colonnade, Canary Wharf, London E14 5HS.

- Ends -

For further information please contact:

Sinclair Pharma plc
Dr Michael Flynn, CEO
Jerry Randall, CFO

Tel: +44 (0) 1483 410 600

Singer Capital Markets Ltd
Shaun Dobson
Claes Spång

Tel: +44 (0)20 3205 7500

Capital MS&L
Mary Clark
Anna Mitchell

Tel +44 (0)20 7307 5340

Notes to Editors:

About Sinclair Pharma Plc: www.sinclairpharma.com.

Sinclair Pharma plc is an international specialty pharmaceutical company providing solutions to treat dermatological, oral care and gynaecological diseases through advanced surface technology and innovative delivery systems. It has a growing sales and marketing operation that is already present in France, Italy and Spain, and a complementary marketing partner network that spans more than 90 countries.

This annual information update is required by, and is being made pursuant to, Article 10 of the Prospectus Directive as implemented in the UK by Prospectus Rule 5.2 and not for any other purpose and neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information which it contains. The information is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Further, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to in it, constitutes, by virtue of this communication, an offer of any securities addressed to any person and it should not be relied on by any person.

"Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: Some or all of the statements in this document that relate to future plans, expectations, events, performances and the like are forward-looking statements, as defined in the US Private Securities Litigation Reform Act of 1995. Actual results of events could differ materially from those described in the forward-looking statements due to a variety of factors.